AlgometRx is a pioneering brand that brings objectivity and precision to pain management. With their innovative technology, the AlgometRx Nociometer®, they enable a fundamental paradigm shift in pain assessment and analgesic prescribing. By analyzing pupil dilation in response to neuroselective stimulation and formulating a nociceptive profile, they can accurately characterize pain type, intensity, and assess the impact of analgesics.

This transformative platform technology can be applied to any population. AlgometRx has an exceptional team behind their advancements in pain management. Led by the founder and Chief Scientific Advisor, Dr.

Julia Finkel, and supported by Chief Operating Officer Kevin Jackson and Chairman of the Board, David Gross, they are committed to revolutionizing pain management. Their innovative approach has earned AlgometRx recognition, including being named a finalist in the 2023 AAPM Innovation Challenge and being awarded two Small Business Innovation Research grants from the NIH. AlgometRx is making waves in the industry and is dedicated to improving pain management for individuals worldwide.

Stay connected with AlgometRx to learn more about their groundbreaking work